Inactive Instrument

TURG POIN

Equities

TPTX

US90041T1088

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from S&P Global BMI Index CI
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from S&P Biotechnology Select Industry Index CI
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from S&P TMI Index CI
Bristol-Myers Squibb Completes Acquisition of Turning Point Therapeutics MT
Turning Point Therapeutics, Inc. Announces Executive Changes CI
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Composite Index CI
Bristol Myers, Turning Point Say Regulatory Waiting Period for Acquisition Expires; Deal to Close Wednesday MT
Bristol-Myers Squibb Company completed the acquisition of Turning Point Therapeutics, Inc. from a group of shareholders.. CI
Biotech stocks pin bounce back hopes on M&A boost RE
Turning Point Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Turning Point Therapeutics, Inc. Provides Operational and Clinical Update CI
Bristol Myers Squibb Extends Turning Point Tender Offer MT
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Biotechnology Index CI
Turning Point Therapeutics to Work With University of Texas MD Anderson Cancer Center on Precision Cancer Therapies MT
Turning Point Therapeutics, Inc. and The University of Texas MD Anderson Cancer Center to Advance Precision Cancer Therapies CI
Guggenheim Downgrades Turning Point Therapeutics to Neutral From Buy, Adjusts Price Target to $76 From $72 MT
SVB Securities Downgrades Turning Point Therapeutics to Market Perform From Outperform, Adjusts Price Target to $76 From $101 MT
Oppenheimer Downgrades Turning Point Therapeutics to Market Perform From Outperform MT
Cowen Downgrades Turning Point Therapeutics to Market Perform from Outperform MT
HC Wainwright Cuts Turning Point Therapeutics to Neutral From Buy, Price Target to $76 From $161 MT
Wells Fargo Downgrades Turning Point Therapeutics to Equalweight From Overweight, Adjusts Price Target to $76 From $85 MT
US Stocks Decline on Friday After Jobs Report MT
US Stocks Finish Holiday-Shortened Week Lower as May Unemployment Rate Holds Steady MT
Sector Update: Health Care Stocks Dragged Lower in Sinking Friday Markets MT
Equities Fall Midday After May Unemployment Rate Remains Unchanged MT
Chart TURG POIN
More charts
Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing and developing therapies that target genetic drivers of cancer to improve the lives of patients. It develops a macrocycle platform from which it designs its pipeline of small, compact tyrosine kinase inhibitors (TKIs). The TKIs generated from its drug discovery platform address unmet needs in TKI naive and resistance settings. The Company's drug candidate, repotrectinib (TPX-0005), is in Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with NTRK+ or ALK+ advanced solid tumors. Its multi-cohort Phase II registrational portion of TRIDENT-1 is ongoing at sites in North America, Europe and the Asia-Pacific regions. The Company's pipeline includes multi-targeted kinase inhibitors: TPX-0046 (a novel RET inhibitor), Elzovantinib (TPX-0022) (a novel MET/CSF1R/SRC inhibitor) and TPX-0131.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock TURG POIN - Nasdaq
  4. News TURG POIN
  5. Turning Point Therapeutics : Receives FDA Fast Track Designation for Investigational Lung Cancer Drug